From: MicroRNAs in colorectal cancer: translation of molecular biology into clinical application
Study | Design | Tumors (n) | Normal1 (n) | Cell lines (n) | miR examined (n) | Technology | miR deregulated in tumors2 |
---|---|---|---|---|---|---|---|
Michael et al. (53) | tumor vs. normal | 14 | 4 | 2 | 28 | Cloning | miR-143, miR-145, miR-21 |
Bandres et al. (54) | tumor vs. normal, TNM staging correlation | 12 | 12 | 15 | 156 | Real-time PCR | miR-31, miR-96, miR-133b, miR-135b, miR-145, miR-183 |
Cummins et al. (55) | miRNAs identification | 4 | 2 | 5 | x | miRAGE | 133 novel microRNAs |
Volinia et al. (56) | tumor vs. normal | 46 | 8 | 0 | 245 | miRNA microarray | miR-24-1, miR-29b-2, miR-20a, miR-10a, miR-32, miR-203, miR-106a, miR-17-5p, miR-30c, miR-223, miR-126, miR-128b, miR-21, miR-24-2, miR-99b prec, miR-155, miR-213, miR-150, miR-107, miR-191, miR-221, miR-9-3 |
Xi et al. (62) | tumor vs. normal, correlation with survival, p53 mutation status | 24 | 24 | 0 | 10 | Real-time PCR | miR-15b, miR-181b, miR-191, miR-200c |
Lanza et al. (58) | MSS tumors vs. MSI tumors | 23 MSS 16 MSI | 0 | 0 | 230 | miRNA microarray | comparison with colon epithelium was not analyzed |
Slaby et al. (22) | tumor vs. normal, clinicopathological parameters correlation | 29 | 6 | 0 | 5 | Real-time PCR | miR-143, miR-145, miR-21, miR-31 |
Nakajima et al. (66) | tumor vs. normal, chemoresponse to S-1 | 21 | 21 | 0 | 5 | Real-time PCR | let-7g, miR-181b, miR-200c |
Monzo et al. (59) | tumor vs. normal and embryonic colon | 22 | 22 | 0 | 156 | Real-time PCR | Stage I (n = 28; miR-106a, miR-125b, miR-145, miR-17-5p, miR-200c, miR-21, miR-34a), Stage II (n = 64; miR-106a, miR-128a, miR-15a, miR-15b, miR-17-5p, miR-181a-c, let-7g, miR-200a-c, miR-21, miR-31, miR-34a, miR-92) selection |
Schetter et al. (23) | tumor vs. normal, correlation with survival, TNM staging | 84 (113)3 | 84 (113)3 | 0 | 389 | miRNA microarray | miR-20a, miR-21, miR-106a, miR-181b, miR-203 |
Schepeler et al. (65) | tumor vs. normal, correlation with recurrence, MSS vs. MSI | 49 | 19 | 0 | 315 | miRNA microarray | miR-145, miR-455, miR-484, miR-101, miR-30b, miR-26b, miR-20a, miR-510, miR-92, miR-513, miR-526c, miR-320, miR-527, miR-432, miR-492, miR-200a, miR-191, miR-302a, miR-512-5p |
Motoyama et al. (57) | tumor vs. normal, correlation with survival | 4 (69)3 | 4 (69)3 | 0 | 455 | miRNA microarray | miR-31, miR-183, miR-17-5p, miR-18a, miR-20a, miR-92, miR-143, miR-145 |
Ng et al. (50) | tumor, plasma vs. control | 5 (25)3 | 5; (20)3 | 0 | 96 | Real-time PCR | miR-18a, miR-223, miR-224, miR-135b, miR-95, miR-106a, miR-19a+b, miR-17-3p, miR-20a, miR-92, miR-221, miR-106b, miR-222, etc.; markers upregulated in both plasma and tumors are given in bold type |